COVID-19 Vaccine Response in Sickle Cell Disease

Completed

Conditions studied: Sickle Cell Disease, COVID-19

In brief

The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.

Key facts

Study ID

NCT05139992

Run by

ASH Research Collaborative

People needed

59

Starts

2021-12-01

Expected to finish

2023-12-31

Last updated by the study team

2025-02-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other)
• Has not received any COVID-19 vaccination prior to enrollment
• Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care
• Willing and able to sign consent

You may not qualify if…

• Unwilling to have labs drawn or complete study requirements.
• Previous therapy curative of SCD (including bone marrow transplant and gene therapy)
• Previous receipt of anti-COVID-19 antibody therapy

Where it is running

• UCSF Benioff Children's Hospital Oakland — Oakland, California, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Montefiore Hospital — The Bronx, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Prisma Health - Upstate — Greenville, South Carolina, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.